Search results
Results from the WOW.Com Content Network
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. [ 1 ]
Repaglinide caused an increased incidence in male rats of benign adenomas (tumors) of the thyroid and liver. [2] No such effect was seen with another drug of this class, nateglinide. [ 3 ]
A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's what a doctor wants you to know.
In those already taking sulphonylureas, there is an increased risk of low blood sugar when taking a medicine in the DPP-4 drug class. [19]Adverse effects include nasopharyngitis, headache, nausea, heart failure, hypersensitivity and skin reactions.
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye ...
Biguanides do not affect the output of insulin, unlike other hypoglycemic agents such as sulfonylureas and meglitinides. Therefore, they are effective in Type 2 diabetics; and in Type 1 diabetes when used in conjunction with insulin therapy. [citation needed]
This article was reviewed by Daniel Z. Lieberman, MD. Overview. You’re tossing and turning, counting sheep for what seems like forever, and still, sleep won’t come.
Due to high costs, some health plans in the US do not cover weight-loss drugs like semaglutide and tirzepatide. [ 74 ] [ 75 ] [ 76 ] In the United States, as of 2024, about half of private employer-sponsored plans cover these drugs, [ 77 ] Federal Medicare Part D does not, and only a few federally-funded, state-administered Medicaid plans do so.